Rib-X Pharmaceuticals Lands Series B Financing Round

  • Feed Type
  • Date
    11/29/2012
  • Company Name
    Rib-X Pharmaceuticals
  • Mailing Address
    300 George Street New Haven, CT 06511
  • Company Description
    Rib-X Pharmaceuticals is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The company’s underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the 50S subunit of the ribosome, which performs an essential role in the fundamental process of protein synthesis.
  • Website
    http://www.rib-x.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    Undisclosed
  • Transaction Round
    Series B
  • Proceeds Purposes
    With this financing, we plan to initiate the Phase 3 program for delafloxacin, which performed successfully in Phase 2b against all endpoints, including the new objective endpoints issued by the FDA.
  • M&A Terms
  • Venture Investor
    Vatera Healthcare Partners
  • Venture Investor
    Warburg Pincus
  • Venture Investor
    ABS Ventures
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.